Grants per year
Personal profile
Certifications and Licenses
| Internal Medicine | |
| Hematology |
Training Experience
| 2006 | Residency, Johns Hopkins Hospital |
| 2010 | Fellowship, Johns Hopkins Hospital |
Education/Academic qualification
MD, Medicine, Emory University
… → 2003
Research interests keywords
- Anemia
- Aplastic Anemia
- Chronic Leukemias
- Clotting Disorders
- Hematological Disorders
- Hematological Malignancies
- Hemostasis
- Immune-Mediated Cytopenias
- Low Platelet Count
- Myelodysplastic Syndrome
- Myeloproliferative Diseases
- Phlebitis
- Platele
Fingerprint
Dive into the research topics where Brady Lee Stein is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #0610-02: A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients wi
Parexel, Constellation Pharmaceuticals, Inc.
10/2/18 → 10/2/24
Project: Research project
-
Prot #INCB-MA-MF-401: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy
Syneos Health, Inc., Incyte Corporation
6/12/18 → 6/12/24
Project: Research project
-
Prot #PAC203: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
PSI Pharma Support America Inc., CTI BioPharma Corp.
10/25/17 → 10/25/23
Project: Research project
-
JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options
Stein, B. L., 2023, In: Leukemia and Lymphoma. 64, 2, p. 292-299 8 p.Research output: Contribution to journal › Review article › peer-review
-
Myeloproliferative Neoplasms, Version 3.2022
Gerds, A. T., Gotlib, J., Ali, H., Bose, P., Dunbar, A., Elshoury, A., George, T. I., Gundabolu, K., Hexner, E., Hobbs, G. S., Jain, T., Jamieson, C., Kaesberg, P. R., Kuykendall, A. T., Madanat, Y., McMahon, B., Mohan, S. R., Nadiminti, K. V., Oh, S., Pardanani, A., & 11 others, Sep 2022, In: JNCCN Journal of the National Comprehensive Cancer Network. 20, 9, p. 1033-1062 30 p.Research output: Contribution to journal › Article › peer-review
Open Access13 Scopus citations -
Lkb1/stk11 is a tumor suppressor in the progression of myeloproliferative neoplasms
Marinaccio, C., Suraneni, P., Celik, H., Volk, A., Wen, Q., Ling, T., Bulic, M., Lasho, T., Koche, R. P., Famulare, C. A., Farnoud, N., Stein, B., Schieber, M., Gurbuxani, S., Root, D. E., Younger, S. T., Hoffman, R., Gangat, N., Ntziachristos, P., Chandel, N. S., & 5 others, 2021, In: Cancer discovery. 11, 6, p. 1398-1410 13 p.Research output: Contribution to journal › Article › peer-review
Open Access19 Scopus citations -
Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials
Stein, B. L., Oct 2021, In: Current Hematologic Malignancy Reports. 16, 5, p. 483-489 7 p.Research output: Contribution to journal › Review article › peer-review
2 Scopus citations -
Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: Prompt resolution of anaphylaxis with the addition of avapritinib
Kudlaty, E., Perez, M., Stein, B. L., Bochner, B. S. & Kuang, F. L., Jun 2021, In: Journal of Allergy and Clinical Immunology: In Practice. 9, 6, p. 2534-2536 3 p.Research output: Contribution to journal › Article › peer-review
5 Scopus citations